Alpha and Omega Semiconductor Introduces Gen3 1200V αSiC MOSFETs Designed to Maximize Efficiency in High Power Applications

SUNNYVALE, Calif.--(BUSINESS WIRE)--May 1, 2025--

Alpha and Omega Semiconductor Limited (AOS) (Nasdaq: AOSL) a designer, developer, and global supplier of a broad range of discrete power devices, wide bandgap power devices, power management ICs, and modules, today introduced the company’s next generation (Gen3) 1200V αSiC MOSFETs designed to maximize efficiency in a growing market of high power applications. These Gen3 MOSFETs provide up to 30 percent improved switching figure-of-merit (FOM) compared to AOS’ previous generation while maintaining low conduction losses at high load conditions. The performance improvements do not compromise ruggedness and reliability, as the Gen3 MOSFETs have full AEC-Q101 qualification, with extended lifetime and HV-H3TRB capabilities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250501227951/en/

As power demands surge in electric vehicles (EVs), AI data centers, and renewable energy systems, inefficiencies in power conversion stages can significantly strain electrical supply and cooling systems. For EV designs, AOS’ Gen3 αSiC MOSFETs enable engineers to create higher power density systems with greater efficiency, reducing battery consumption and extending vehicle range. Future AI data centers adopting high-voltage DC (HVDC) architectures, such as 800V or ±400V, will benefit from reduced losses and increased power density to meet growing power requirements. To support these higher system voltages, AOS’ Gen3 1200V devices will be critical for enabling new topologies with the necessary efficiency.

The new AOS Gen3 1200V MOSFETs are available with an on-resistance (Rds(on)) range from 15mOhm (AOM015V120X3Q) to 40mOhm (AOM040V120X3Q) in a TO27-4L package. AOS plans to roll out its Gen3 MOSFETs in additional surface mount and topside cooled packages as well as in case modules. AOS has also qualified a larger Gen3 1200V/11mOhm MOSFET die designed for high-power EV traction inverter modules and is available for wafer sales.

“Electric vehicles and AI are transforming industries, but they require advanced power systems that can maintain efficiency even as energy demands increase,” said David Sheridan, Vice President of Wide Bandgap products at AOS. “We’re excited that this next generation of AOS αSiC MOSFETs can deliver the performance our customers require while making a positive environmental impact.”

Technical Highlights

Pricing and Availability

Please contact your local sales representative for sample availability and pricing.

About AOS

Alpha and Omega Semiconductor Limited, or AOS, is a designer, developer, and global supplier of a broad range of discrete power devices, wide bandgap power devices, power management ICs, and modules, including a wide portfolio of Power MOSFET, SiC, IGBT, IPM, TVS, HV Gate Drivers, Power IC, and Digital Power products. AOS has developed extensive intellectual property and technical knowledge that encompasses the latest advancements in the power semiconductor industry, which enables us to introduce innovative products to address the increasingly complex power requirements of advanced electronics. AOS differentiates itself by integrating its Discrete and IC semiconductor process technology, product design, and advanced packaging know-how to develop high-performance power management solutions. AOS’ portfolio of products targets high-volume applications, including personal computers, graphics cards, data centers, AI servers, smartphones, consumer and industrial motor controls, TVs, lighting, automotive electronics, and power supply units for various equipment. For more information, please visit www.aosmd.com.

Forward-Looking Statements

This press release contains forward-looking statements that are based on current expectations, estimates, forecasts, and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, references to the efficiency and capability of new products and the potential to expand into new markets. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include but are not limited to, the actual product performance in volume production, the quality and reliability of the product, our ability to achieve design wins, the general business and economic conditions, the state of the semiconductor industry, and other risks as described in the Company’s annual report and other filings with the U.S. Securities and Exchange Commission. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date unless otherwise stated, and AOS undertakes no duty to update such information except as required under applicable law.

Alpha and Omega Semiconductor Introduces Gen3 1200V αSiC MOSFETs Designed to Maximize Efficiency in High Power Applications

NEW YORK (AP) — Luigi Mangione’s lawyers contend that Attorney General Pam Bondi’s decision to seek the death penalty against him in the killing of UnitedHealthcare CEO Brian Thompson was tainted by her prior work as a lobbyist at a firm that represented the insurer’s parent company.

Bondi was a partner at Ballard Partners before leading the Justice Department’s charge to turn Mangione’s federal prosecution into a capital case, creating a “profound conflict of interest” that violated his due process rights, his lawyers wrote in a court filing late Friday. They want prosecutors barred from seeking the death penalty and some charges thrown out. A hearing is scheduled for Jan. 9.

By involving herself in the death penalty decision and making public statements suggesting that Mangione deserves execution, Bondi broke a vow she made before taking office in February that she would follow ethical regulations and bow out of matters pertaining to Ballard clients for a year, Mangione’s lawyers said.

They argued Bondi has continued to profit from her work for Ballard — and, indirectly, from its work for UnitedHealth Group — through a profit-sharing arrangement with the lobbying firm and a defined contribution plan it administers.

The “very person” empowered to seek Mangione’s death "has a financial stake in the case she is prosecuting,” his lawyers wrote. Her conflict of interest “should have caused her to recuse herself from making any decisions on this case,” they added.

Messages seeking comment were left for the Justice Department and Ballard Partners.

Bondi announced in April that she was directing Manhattan federal prosecutors to seek the death penalty, declaring even before Mangione was formally indicted that capital punishment was warranted for a “premeditated, cold-blooded assassination that shocked America.”

Thompson, 50, was killed Dec. 4, 2024, as he walked to a Manhattan hotel for UnitedHealth Group’s annual investor conference. Surveillance video showed a masked gunman shooting him from behind. Police say “delay,” “deny” and “depose” were written on the ammunition, mimicking a phrase used to describe how insurers avoid paying claims.

Mangione, 27, the Ivy League-educated scion of a wealthy Maryland family, was arrested five days later at a McDonald’s in Altoona, Pennsylvania, about 230 miles (about 370 kilometers) west of Manhattan. He has pleaded not guilty to federal and state murder charges. The state charges carry the possibility of life in prison. Neither trial has been scheduled.

Friday’s filing put the focus back on Mangione’s federal case a day after a marathon pretrial hearing ended in his fight to bar prosecutors in his state case from using certain evidence found during his arrest, such as a gun that police said matched the one used to kill Thompson and a notebook in which he purportedly described his intent to “wack” a health insurance executive. A ruling isn't expected until May.

Mangione’s defense team, led by the husband-and-wife duo of Karen Friedman-Agnifilo and Marc Agnifilo, zeroed in on Bondi’s past lobbying work as they seek to convince U.S. District Judge Margaret Garnett to rule out capital punishment, throw out some charges and exclude the same evidence they want suppressed from the state case.

In a September court filing, Mangione’s lawyers argued that Bondi’s announcement that she was ordering prosecutors to seek the death penalty — which she followed with Instagram posts and a TV appearance — showed the decision was “based on politics, not merit.” They also said her remarks tainted the grand jury process that resulted in his indictment a few weeks later.

Bondi’s statements and other official actions — including a highly choreographed perp walk that saw Mangione led up a Manhattan pier by armed officers, and the Trump administration’s flouting of established death penalty procedures — “have violated Mr. Mangione’s constitutional and statutory rights and have fatally prejudiced this death penalty case,” his lawyers said.

In a court filing last month, federal prosecutors argued that “pretrial publicity, even when intense, is not itself a constitutional defect.”

Rather than dismissing the case outright or barring the government from seeking the death penalty, prosecutors argued, the defense’s concerns can best be alleviated by carefully questioning prospective jurors about their knowledge of the case and ensuring Mangione’s rights are respected at trial.

“What the defendant recasts as a constitutional crisis is merely a repackaging of arguments” rejected in previous cases, prosecutors said. “None warrants dismissal of the indictment or categorical preclusion of a congressionally authorized punishment.”

Mangione’s lawyers said they want to investigate Bondi’s ties to Ballard and the firm’s relationship with UnitedHealth Group and will ask for various materials, including details of Bondi’s compensation from the firm, any direction she's given Justice Department employees regarding the case or UnitedHealthcare, and sworn testimony from “all individuals with personal knowledge of the relevant matters."

FILE - This image taken from video released by Pennsylvania State Police shows Luigi Mangione, a suspect in the fatal shooting of UnitedHealthcare CEO Brian Thompson, at a McDonald's in Altoona, Pa., on Dec. 9, 2024. (Pennsylvania State Police via AP)

Luigi Mangione appears in Manhattan Criminal Court for an evidence hearing, Thursday , Dec. 18, 2025, in New York. (Curtis Means/Pool Photo via AP)